|
| Target | Drug | Clinical trial |
|
Vascular endothelial growth factor | Tyrosine kinase inhibitors | Sunitinib | + | Phase II trial: non:GIST sarcoma [18]. |
| | | + | Phase II trial: leiomyosarcoma, liposarcoma, and malignant fibrous histiocytoma. [19]. |
| | | − | Phase II study: treatment of recurrent/persistent uterine leiomyosarcoma [20]. |
| | Sorafenib | + | Phase II trial: patients with metastatic or recurrent sarcomas [28]. |
| | | + | Phase II trial: efficacy of sorafenib in STS [31]. |
| | | + |
Phase II trial: relapsed and unresectable high-grade osteosarcoma [29]. |
| | | + | Phase II trial: advanced vascular sarcoma, high grade liposarcoma and leiomyosarcoma [30]. |
| | Pazopanib | + | Phase II trial: patients with relapsed or refractory advanced STS [32]. |
| | | + | Phase III trial: placebo-controlled randomized trial in advanced STS [33]. |
| | Dasatinib | x | No results published. |
| Anti-VEGF antibodies | Bevacizumab | + | Phase II trial: doxorubicin and bevacizumab in patients with metastatic STS [43]. |
| | | + | Phase IB trial: efficacy of bevacizumab in combination with other drugs [44]. |
|
Insulin-like growth factor | Tyrosine kinase inhibitors | Clinical development | x | No results published. |
| Anti-IGFR1 antibodies | AMG 479 | + | Phase I trial: response of sarcoma patients to a fully monoclonal antibody to IGFR-1 [68]. |
| | Figitumumab | − | Phase I trial: different sarcoma patients [70]. |
| | IMC-A12 (cixutumumab) | + | Phase II trial: patients with advanced or metastatic STS and Ewing Sarcoma [91]. |
|
Mammalian target of rapamycin | mTORC1 tyrosine kinase inhibitors | Sirolimus | − | Phase II trial: combination with cyclophosphamide in sarcomas [91]. |
| | Temsirolimus | + | Phase II trial: temsirolimus in pediatric patients with neuroblastoma, high-grade glioma, and rhabdomyosarcoma [95]. |
| | | − |
Phase II trial: treatment in STS patients [94] |
| | | + | Phase II trial: everolimus in STS or bone sarcoma [97] |
| | Everolimus | + | Phase II trial: treatment in patients with advanced bone and soft tissue sarcomas [99]. |
| | Ridaforolimus | + | Phase III trial: placebo-controlled randomized sarcoma patient [99]. |
|
Hepatocyte growth factor receptor | MET inhibitors | ARQ197 | + | Phase II trial: patients with microph thalmia transcription-family-(MiT-) associated tumors [107]. |
Virus | Tumor cell | Oncolytic poxvirus | + | Phase I trial: oncolytic poxvirus in different cancer patients [109]. |
Insulin-like growth factor/ mammalian target of rapamycin | Tyrosine kinase inhibitors | Figitumumab/ everolimus | + | Phase I trial: advanced sarcoma patients and other solid tumors [114]. |
Cixutumumab/ temsirolimus | + | Phase I trial: patients with advanced cancer including sarcomas [115]. |
|
Other targets | ALK inhibitors | Crizotinib | + | Phase I trial: inflammatory myofibroblastic tumor with ALK overexpression [116]. |
| HDAC inhibitors | | + | Ongoing clinical trials. |
| PI3K/mTOR | NVP-BEZ235 | + | Ongoing clinical trials. |
|